Citigroup Inc. Sells 12,533 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Citigroup Inc. cut its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 39.9% during the fourth quarter, Holdings Channel.com reports. The firm owned 18,890 shares of the medical research company’s stock after selling 12,533 shares during the period. Citigroup Inc.’s holdings in Charles River Laboratories International were worth $4,116,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Concord Wealth Partners purchased a new stake in Charles River Laboratories International during the fourth quarter valued at approximately $33,000. Huntington National Bank increased its stake in shares of Charles River Laboratories International by 53.7% in the third quarter. Huntington National Bank now owns 189 shares of the medical research company’s stock worth $37,000 after acquiring an additional 66 shares during the period. Allworth Financial LP grew its position in Charles River Laboratories International by 60.0% during the fourth quarter. Allworth Financial LP now owns 168 shares of the medical research company’s stock valued at $37,000 after buying an additional 63 shares during the period. Quent Capital LLC grew its position in Charles River Laboratories International by 28.6% during the third quarter. Quent Capital LLC now owns 198 shares of the medical research company’s stock valued at $39,000 after buying an additional 44 shares during the period. Finally, Gradient Investments LLC grew its position in Charles River Laboratories International by 6,200.0% during the fourth quarter. Gradient Investments LLC now owns 189 shares of the medical research company’s stock valued at $41,000 after buying an additional 186 shares during the period. 97.80% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

CRL has been the topic of several research analyst reports. Jefferies Financial Group dropped their target price on shares of Charles River Laboratories International from $233.00 to $203.00 and set a “hold” rating on the stock in a research report on Tuesday, March 28th. TheStreet cut shares of Charles River Laboratories International from a “b-” rating to a “c” rating in a report on Thursday, May 11th. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Charles River Laboratories International from $260.00 to $250.00 in a report on Friday, May 12th. Credit Suisse Group lowered their price target on shares of Charles River Laboratories International from $260.00 to $255.00 in a report on Friday, May 12th. Finally, Guggenheim upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $255.00 price objective for the company in a research report on Thursday, February 23rd. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $260.73.

Insiders Place Their Bets

In other news, EVP Joseph W. Laplume sold 345 shares of the company’s stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $190.39, for a total value of $65,684.55. Following the transaction, the executive vice president now owns 24,026 shares in the company, valued at approximately $4,574,310.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Down 0.5 %

Charles River Laboratories International stock opened at $198.33 on Monday. The company has a 50-day simple moving average of $195.91 and a 200-day simple moving average of $218.75. The firm has a market capitalization of $10.15 billion, a P/E ratio of 20.51, a P/E/G ratio of 1.38 and a beta of 1.34. The company has a debt-to-equity ratio of 0.88, a quick ratio of 1.21 and a current ratio of 1.48. Charles River Laboratories International, Inc. has a one year low of $181.22 and a one year high of $262.00.

Charles River Laboratories International (NYSE:CRL – Get Rating) last issued its quarterly earnings results on Wednesday, February 22nd. The medical research company reported $2.98 earnings per share for the quarter, beating analysts’ consensus estimates of $2.75 by $0.23. Charles River Laboratories International had a net margin of 12.13% and a return on equity of 20.12%. The company had revenue of $1.10 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same period in the prior year, the company earned $2.49 EPS. Charles River Laboratories International’s revenue was up 21.5% on a year-over-year basis. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 10.28 earnings per share for the current year.

Charles River Laboratories International Company Profile

(Get Rating)

Charles River Laboratories International, Inc is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices, and therapies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions.